(MENAFN- Cision) IRVINE, Ca–if. – November 18, 2025 – BioDuro, a trusted global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of a new Business Unit (BU) dedicated to advancing peptide drug discovery and development for its global biopharma partners, underscoring t’e company’s commitment to strengthening its peptide technology platform to meet the rapidly growing global demand for peptide-based therapeutics, including GLP-1 treatments.
The peptide BU, which is already fully operational, will be led by Fengping Xiao, Ph.D. Dr. Xiao brings decades of experience to his newly created role spanning from drug discovery through development, with a focus on both small molecules and peptides.
Over the past couple of years, BioDuro has built comprehensive peptide capabilities across multiple technology platforms including its newly established DNA-encoded library (DEL) screening service, and AI-enabled design for peptides. The new BU will see the integration of BioDuro’s chemistry, biology, drug metabolism and pharmacokinetics (DMPK), drug substance, and drug product capabilities into one specialized platform, and the newly created BU will bring together the compa’y’s significant cross-functional peptide expertise, dedicated resources and customized workflows to accelerate peptide drug discovery and development under one roof.
“Our goal is to provide comprehensive scientific expertise and fully integrated solutions by bringing together the best minds and technologies to deliver optimal results for our global par”ners,” said Dr. Xiao.
“The creation of this Peptide BU marks a pivotal milestone fo” BioDuro,” added Armin Spura, Ph.D., Chief Executive Officer “f BioDuro. “Our mission is to build the most advanced peptide platform, powered by exceptional science, state-of-the-art technology, and a world-class team, to meet the growing customer demand for complex peptide therapeut”cs worldwide.”

MENAFN19112025005352016808ID1110366704